Revenue and Profit - Revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.44% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 14,292,867.60, an increase of 22.64% year-over-year[6] - Total operating revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.4% compared to CNY 93,280,186.12 in Q1 2021[18] - The company reported a net profit of CNY 14,797,683.82 for Q1 2022, compared to a net profit of CNY 13,284,381.40 in Q1 2021[18] - The net profit for Q1 2022 was CNY 14,292,867.60, an increase of 22.3% compared to CNY 11,653,981.88 in Q1 2021[19] - Operating profit for Q1 2022 reached CNY 17,636,111.54, up from CNY 14,153,914.49 in the same period last year, reflecting a growth of 24.3%[19] - The total comprehensive income for Q1 2022 was CNY 14,292,867.60, up from CNY 11,653,981.88 in Q1 2021, reflecting an increase of 22.3%[20] Expenses and Costs - R&D expenses totaled CNY 6,108,108.78, representing 7.56% of revenue, an increase of 1.6 percentage points[7] - Total operating costs for Q1 2022 were CNY 65,947,116.57, down 17.5% from CNY 79,995,804.72 in Q1 2021[18] - Research and development expenses for Q1 2022 were CNY 5,112,082.43, slightly up from CNY 5,011,994.78 in Q1 2021[18] - The company incurred a credit impairment loss of CNY 429,227.24 in Q1 2022, compared to CNY 624,004.03 in Q1 2021, showing a decrease of 31.2%[19] - The company incurred financial expenses of CNY 267,075.46 in Q1 2022, contrasting with a financial income of CNY 252,479.62 in Q1 2021[25] Cash Flow and Liquidity - Operating cash flow for the quarter was CNY 29,565,224.06, up 20.12% from the previous year[7] - Cash flow from operating activities generated a net amount of CNY 29,565,224.06, compared to CNY 24,612,688.81 in Q1 2021, indicating a year-over-year increase of 20.0%[21] - Total cash and cash equivalents at the end of Q1 2022 amounted to CNY 268,158,720.07, significantly higher than CNY 135,737,596.01 at the end of Q1 2021, representing an increase of 97.5%[21] - The company reported cash inflows from investment activities of CNY 201,170,235.62, with a net cash flow from investment activities of CNY 19,110,356.37, compared to a net outflow of CNY 17,353,559.51 in Q1 2021[21] - The company's cash outflow from operating activities totaled CNY 126,590,112.56 in Q1 2022, compared to CNY 110,059,935.17 in Q1 2021, indicating an increase of 15.1%[21] Assets and Liabilities - Total assets at the end of the quarter were CNY 992,618,993.49, an increase of 3.76% from the end of the previous year[7] - Cash and cash equivalents as of March 31, 2022, were CNY 269,428,720.07, an increase from CNY 211,564,862.66 as of December 31, 2021[14] - Inventory as of March 31, 2022, was CNY 113,310,556.00, up from CNY 101,363,001.75 as of December 31, 2021[15] - Total liabilities as of March 31, 2022, were CNY 192,911,128.84, an increase from CNY 171,480,668.76 as of December 31, 2021[16] - The company’s total equity as of March 31, 2022, was CNY 799,707,864.65, compared to CNY 785,137,100.85 as of December 31, 2021[17] Shareholder Information - The company reported a total of 6,406 common shareholders at the end of the reporting period[10] - The largest shareholder, Chengdu Sainuo Investment Co., Ltd., holds 30,000,000 shares, representing 37.5% of total shares[10] Other Financial Metrics - Basic and diluted earnings per share were both CNY 0.18, a decrease of 5.26% compared to the same period last year[7] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.18, slightly down from CNY 0.19 in Q1 2021[20] - The company’s total equity as of the end of Q1 2022 was CNY 509,521,123.28, compared to CNY 509,328,982.40 at the end of Q1 2021[25]

Financial Performance - The company's operating revenue for Q3 2021 was ¥85,482,938.78, a decrease of 10.19% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥19,024,936.15, an increase of 83.89% year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥18,352,139.50, up 93.81% compared to the previous year[5]. - Net profit for the third quarter of 2021 was ¥43,033,916.95, compared to ¥41,656,637.29 in the previous year, representing a growth of approximately 3.3%[23]. - Total operating revenue for the first three quarters of 2021 reached ¥279,121,290.27, an increase from ¥270,905,465.33 in the same period of 2020, reflecting a growth of approximately 0.8%[22]. - Total operating costs for the same period were ¥230,546,720.25, up from ¥223,621,046.30, indicating an increase of about 3.9%[22]. - Basic earnings per share for the reporting period were ¥0.24, an increase of 41.18% year-on-year[6]. - Basic and diluted earnings per share for the third quarter were both ¥0.62, down from ¥0.69 in the same quarter of the previous year[24]. - The company reported a financial income of ¥2,594,587.88, up from ¥1,454,015.01, showing an increase of about 78.3%[22]. - The total comprehensive income for the third quarter was ¥43,033,916.95, consistent with the net profit, indicating no other comprehensive income adjustments[24]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥907,425,796.89, reflecting a growth of 53.03% from the end of the previous year[6]. - As of September 30, 2021, the total current assets amounted to ¥602,984,005.70, a significant increase from ¥336,093,024.41 at the end of 2020, representing an increase of approximately 79.5%[16]. - The total assets of the company as of September 30, 2021, were ¥907,425,796.89, compared to ¥592,984,864.45 at the end of 2020, reflecting an increase of approximately 53.1%[17]. - The company reported a total non-current assets of ¥304,441,791.19, up from ¥256,891,840.04, which is an increase of around 18.4%[17]. - The company's total liabilities decreased from ¥155,410,598.68 to ¥140,785,431.76, a reduction of about 9.4%[22]. - The total liabilities were not explicitly stated, but accounts payable decreased to ¥5,257,078.05 from ¥20,666,627.10, indicating a reduction of approximately 74.6%[17]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥28,604,702.44, down 53.65% compared to the previous year[6]. - Cash inflows from operating activities totaled ¥396,307,890.00 for the first three quarters, compared to ¥370,248,224.86 in the same period of 2020, reflecting an increase of about 7.0%[25]. - The net cash flow from operating activities was $28,604,702.44, a decrease of 53.8% compared to $61,720,516.49 in the previous year[26]. - Total cash outflow from operating activities amounted to $367,703,187.56, up 19.1% from $308,527,708.37 year-over-year[26]. - The net cash flow from investing activities was -$63,765,550.05, compared to -$39,790,550.95 in the same period last year, indicating a significant increase in investment outflows[26]. - Cash inflow from financing activities was $285,016,000, with no cash inflow recorded in the previous year[26]. - The net cash flow from financing activities was $285,016,000, contrasting with a net outflow of $475,309.33 in the previous year[26]. - The total cash and cash equivalents at the end of the period reached $377,808,156.41, a substantial increase from $124,263,977.90 year-over-year[27]. - The cash and cash equivalents net increase for the quarter was $249,551,678.76, compared to $21,314,496.95 in the same quarter last year[27]. - The company reported a cash outflow of $63,765,550.05 from investing activities, primarily due to capital expenditures[26]. Research and Development - Research and development expenses totaled ¥3,418,356.09, a decrease of 58.57% compared to the same period last year[6]. - Research and development expenses for the third quarter were ¥8,920,158.71, a decrease from ¥11,936,006.06 in the previous year, indicating a reduction of approximately 25.3%[22]. - The company has 27 self-developed projects, with 11 projects completed and entering the review stage or about to be reported, and 5 projects in clinical trial stages[10]. - The company has ongoing development expenditures amounting to ¥7,826,561.29, which increased from ¥4,736,120.07, reflecting a growth of about 65.5%[17]. Shareholder Information - The top shareholder, Chengdu Sainuo Investment Co., Ltd., holds 37.50% of the shares, totaling 30,000,000 shares[12]. - The company has no reported financing or margin trading activities among the top shareholders[13].

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company expects a revenue growth forecast of 25% for the second half of 2021, driven by new product launches and market expansion strategies[1]. - ChengDu Sheng Nuo Biotec Co., Ltd. reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 100 million, representing a 25% growth compared to the same period in 2020[15]. - Future outlook indicates a projected revenue growth of 20% for the second half of 2021, driven by new product launches and market expansion strategies[15]. - The company's operating revenue for the reporting period (January to June) was CNY 193,638,351.49, an increase of 10.20% year-on-year[23]. - The net profit attributable to shareholders was CNY 24,008,980.80, a decrease of 23.32% compared to the same period last year[24]. - The net cash flow from operating activities decreased by CNY 37,183,863.49, primarily due to increased purchases of raw materials and higher market promotion expenses[25]. - The net assets attributable to shareholders increased by 70.79% to CNY 747,337,532.78, and total assets rose by 55.25% to CNY 920,595,710.10, mainly due to funds raised from the IPO[26]. - Basic and diluted earnings per share decreased by 26.92% to CNY 0.38, impacted by the dilution effect from the issuance of 20 million shares[28]. - The company achieved a sales revenue of 193.64 million RMB, representing a year-on-year growth of 10.20%[98]. - Operating costs increased by 20.39% to 47.29 million RMB, primarily due to rising costs in pharmaceutical research and recycled chemical reagents[98]. - Net profit attributable to shareholders decreased by 23.32% to 24.01 million RMB, while the net profit excluding non-recurring gains and losses fell by 22.17% to 22.79 million RMB[98]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2021[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - The company has expanded its user base, with active users increasing by 30% year-over-year, now totaling 500,000 users[15]. - The company plans to enhance its distribution network, targeting a 20% increase in market penetration by the end of 2022[15]. Research and Development - Research and development expenses increased by 30% compared to the previous year, focusing on innovative biopharmaceutical products[1]. - The company is actively developing innovative drugs, with three new drug candidates expected to enter clinical trials by the end of 2021[15]. - Research and development expenses have increased by 10%, reflecting the company's commitment to innovation and product development[15]. - The company invested 4.44% of its operating revenue in R&D, an increase of 0.81 percentage points year-on-year[22]. - Total R&D investment increased by 34.87% year-on-year, reaching ¥8,592,243.84, driven by clinical trial approvals for key projects[81]. - The proportion of R&D investment capitalized increased by 14.24 percentage points, reflecting the progress of clinical trials for key projects[82]. - The company has provided pharmaceutical research services for over 30 innovative peptide drug projects, with 1 approved for market and 7 in clinical trial stages[74]. - The company has ongoing projects with 10 varieties submitted for registration and 3 varieties granted clinical trial approval, indicating a strong pipeline for future products[118]. Operational Efficiency and Cost Management - The company has implemented new strategies to improve operational efficiency, aiming for a 15% reduction in production costs by the end of 2021[1]. - The company has established a robust quality management system in compliance with GMP standards to ensure consistent production quality[46]. - The production process adheres to GMP standards, with rigorous quality control measures in place throughout the manufacturing cycle[56]. - The company has made significant investments in pollution control facilities and production process optimization to minimize environmental impact[142]. Risk Factors and Challenges - The company has identified several risk factors, including regulatory changes and market competition, which may impact future performance[1]. - The decline in net profit was attributed to limited production capacity due to the need to meet GMP conditions for CDMO services[24]. - The average price drop for drugs due to centralized procurement is approximately 52%-53%, which poses a risk to the sustainability of the company's formulation sales[108]. - The company faces risks of declining sales revenue for its main API, Bevacizumab, if its major client, Fresenius, loses market share in the U.S.[109]. - The company faces risks related to R&D failures, market acceptance of new products, and potential loss of core technical personnel, which could impact future performance[120][121][122]. Environmental Compliance and Sustainability - The company emphasizes strict compliance with environmental laws and has implemented effective management of pollutants generated during production[142][143]. - The company has established emergency response plans for environmental incidents, which have been registered with the Chengdu Deyang County Ecological Environment Bureau[146][148]. - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental authorities during the reporting period[143]. - The company has committed to maintaining a lock-up period for major shareholders, preventing the transfer of shares for 36 months post-IPO[158]. - The company has a focus on environmental protection and sustainable practices, aligning with national and industry standards[153]. Shareholder Commitments and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, with a two-year lock-up period for any reductions thereafter[161]. - The company will adhere to the regulations set forth by the China Securities Regulatory Commission regarding share transfers and reductions[165]. - The company has established measures to avoid competition among its major shareholders and related parties, ensuring a clear operational focus[191]. - The company has made commitments regarding the handling of non-operating fund occupation by major shareholders and related parties, ensuring compliance with regulations[192].